関連する実験動画
Updated: May 5, 2026
08:56
Study of Experimental Organ Donation Models for Lung Transplantation
Published on: March 15, 2024
2.4K
病院外での致死性肺栓塞における民族的差異
Yingying Tang1, Barbara Sampson, Stephanie Pack
1Molecular Genetics Laboratory, Department of Forensic Biology, New York City Office of Chief Medical Examiner, New York, NY 10016, USA. ytang@ocme.nyc.gov
Circulation
|May 11, 2011
まとめ
病院外での致死性肺栓塞 (PE) は,黒人とヒスパニック系の人々に不釣り合いな影響を及ぼし,彼らもより若い年齢で死亡します. 肥満やFactor V Leidenのような遺伝的要因は,PEによる早期死亡と関連しています.
科学分野:
- 医学科学 医学科学 医学科学 医学科学
- エピデミオロジー エピデミオロジー
- 公衆衛生は公衆衛生である.
背景:
- 病院内肺栓塞 (PE) はよく研究されているが,病院外での致死性PEには広範な研究が欠けている.
- この研究は,ニューヨーク市内の病院の外で発生する致命的なPE症例を調査しています.
研究 の 目的:
- 病院外での致死性PEの流行病学を分析する.
- 致死性PE症例におけるリスク要因と人口統計学的差異を特定する.
主な方法:
- 578件の連続した病院外で死亡したPE症例の体系的な評価.
- 解剖,毒理学,微生物学,遺伝子検査が行われました.
- 人種,肥満,遺伝子変異を含む発生率とベースラインの特徴を分析した.
主要な成果:
- 病院外での致死性PEの人種調整された発生率は,黒人個体 (3.73/100,000) で最も高く,次いで白人 (1.15/100,000) とヒスパニック (0.93/100,000) の個体でした.
- 肥満 (BMI ≥30 kg/m2) は,致死性PE症例では2.5~3倍高かった.
- プロトロンビンG20210Aキャリアの頻度は2〜10倍高かった; V因子レイデンキャリアと肥満は,死亡時の年齢が低いと関連していた.
結論:
- 病院外での致死性PEでは,ニューヨーク市内の民族間で有意な疫学的格差が存在します.
- 非白人の民族,ファクターV・ライデン,肥満は,PEによる死亡の年齢の低さに関連しています.
関連する概念動画
01:21Acute Respiratory Failure-II
1.8K
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.8K
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
160
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160
01:29Pulmonary Embolism I: Introduction
1.5K
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
1.5K
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
760
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
760
01:27Pulmonary Embolism III: Nursing Management
756
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
756
01:19Pulmonary Embolism I: Introduction
65
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
65